AR068669A1 - Metodo para aliviar la queratoconjuntivitis seca - Google Patents

Metodo para aliviar la queratoconjuntivitis seca

Info

Publication number
AR068669A1
AR068669A1 ARP080104346A ARP080104346A AR068669A1 AR 068669 A1 AR068669 A1 AR 068669A1 AR P080104346 A ARP080104346 A AR P080104346A AR P080104346 A ARP080104346 A AR P080104346A AR 068669 A1 AR068669 A1 AR 068669A1
Authority
AR
Argentina
Prior art keywords
compounds
topical
salts
group
civamide
Prior art date
Application number
ARP080104346A
Other languages
English (en)
Inventor
Joel E Bernstein
Original Assignee
Winston Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winston Lab Inc filed Critical Winston Lab Inc
Publication of AR068669A1 publication Critical patent/AR068669A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

La incorporacion opcional a la formulacion intranasal de un corticosteroide topico o un compuesto anestésico topico se usa para reducir la sensacion punzante o quemante transitoria que en ocasiones acompana la administracion intranasal de capsaicinoides. Reivindicacion 1: Un método para tratar queratoconjuntivitis seca mediante la administracion de una cantidad efectiva de una composicion, caracterizado porque comprende compuestos capsaicinoides, adecuados para la administracion intranasal sobre la mucosa nasal. Reivindicacion 2: El método de acuerdo con la reivindicacion 1 caracterizado porque dicho compuesto capsaicinoide se selecciona de! grupo que consiste de capsaicina, civamida, compuestos acetilados de capsaicina y civamida, y las sales de todos los capsaicinoides antes mencionados. Reivindicacion 5: El método de acuerdo con la reivindicacion 2, caracterizado porque además comprende un anestésico topico o un corticosteroide topico. Reivindicacion 6: El método de acuerdo con la reivindicacion 5, caracterizado porque dicho anestésico topico se selecciona del grupo que incluye pramoxina, lidocaína, dibucaína, prilocaína, sus sales y compuestos de esencialmente la misma funcion. Reivindicacion 8: El método de acuerdo con la reivindicacion 5, caracterizado porque dicho corticosteroide topico se selecciona de un grupo que incluye hidrocortisona, triamcinolona, betametasona, sus sales o compuestos relacionados.
ARP080104346A 2007-10-05 2008-10-03 Metodo para aliviar la queratoconjuntivitis seca AR068669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/868,286 US20090093446A1 (en) 2007-10-05 2007-10-05 Method for alleviating keratoconjunctivitis sicca

Publications (1)

Publication Number Publication Date
AR068669A1 true AR068669A1 (es) 2009-11-25

Family

ID=40523784

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104346A AR068669A1 (es) 2007-10-05 2008-10-03 Metodo para aliviar la queratoconjuntivitis seca

Country Status (13)

Country Link
US (1) US20090093446A1 (es)
EP (1) EP2094256A4 (es)
JP (1) JP2009545634A (es)
KR (1) KR20090080017A (es)
CN (1) CN101616663A (es)
AR (1) AR068669A1 (es)
AU (1) AU2007349197A1 (es)
BR (1) BRPI0710595A2 (es)
CA (1) CA2644733A1 (es)
IL (1) IL198657A0 (es)
MX (1) MX2008013039A (es)
NZ (1) NZ571467A (es)
WO (1) WO2009045224A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166925B2 (en) 2018-08-23 2021-11-09 Elorac, Inc. Method for alleviating keratoconjunctivitis sicca

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019203A2 (en) * 2010-08-03 2012-02-09 Dynova Laboratories, Inc. Therapeutic agent for intranasal administration and method of making and using same
WO2012068247A1 (en) 2010-11-16 2012-05-24 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
PL2729139T3 (pl) * 2011-07-07 2021-05-31 Eva MILLQVIST Produkt zmniejszający kaszel
JP2015526481A (ja) * 2012-08-24 2015-09-10 ブイアール１ インコーポレイテッド 片頭痛の治療用組成物
JP6795975B2 (ja) 2013-04-19 2020-12-02 オキュリーブ， インコーポレイテッド 鼻刺激デバイス及び方法
PT3209295T (pt) 2014-10-20 2021-02-05 Oyster Point Pharma Inc Métodos de tratamento das condições oculares
CA2965186A1 (en) * 2014-10-22 2016-04-28 Oculeve, Inc. Stimulation devices and methods for treating dry eye
WO2017177024A1 (en) 2016-04-07 2017-10-12 Oyster Point Pharma, Inc. Methods of treating ocular conditions
AU2017260237A1 (en) 2016-05-02 2018-11-22 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
TW202019424A (zh) * 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
WO2020040769A1 (en) * 2018-08-23 2020-02-27 Elorac, Inc. Method and compositions for alleviating keratoconjunctivitis sicca

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134166A (en) * 1988-12-02 1992-07-28 Genderm Corporation Method for treating nasal disorders and headaches
CA2017383A1 (en) * 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
US5063060A (en) * 1989-12-19 1991-11-05 Cisco Limited Partnership Compositions and method for treating painful, inflammatory or allergic disorders
DE59408028D1 (de) * 1993-09-30 1999-05-06 Medichemie Ag Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie
CH690023A5 (de) * 1996-02-02 2000-03-31 Medichemie Ag Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut.
US6403598B1 (en) * 1998-01-30 2002-06-11 R-Tech Ueno, Ltd. Ophthalmic composition
JP4653516B2 (ja) * 2004-02-27 2011-03-16 扶桑薬品工業株式会社 涙液分泌促進ペプチドおよびその組成物
DE102004063363A1 (de) * 2004-06-28 2006-01-19 Weber, Erhard, Dr. Capsaicin-haltige Arzneien zur Behandlung von Bronchial-Infekten und Allergien
EA200701131A1 (ru) * 2004-11-24 2007-12-28 Алгоркс Фармасьютикалз, Инк. Гелеобразная препаративная форма капсаициноида и способы её применения

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166925B2 (en) 2018-08-23 2021-11-09 Elorac, Inc. Method for alleviating keratoconjunctivitis sicca
US11478439B2 (en) 2018-08-23 2022-10-25 Elorac, Inc. Method for alleviating keratoconjunctivitis sicca

Also Published As

Publication number Publication date
CN101616663A (zh) 2009-12-30
IL198657A0 (en) 2010-02-17
US20090093446A1 (en) 2009-04-09
AU2007349197A1 (en) 2009-04-23
CA2644733A1 (en) 2009-04-05
EP2094256A1 (en) 2009-09-02
KR20090080017A (ko) 2009-07-23
JP2009545634A (ja) 2009-12-24
WO2009045224A1 (en) 2009-04-09
MX2008013039A (es) 2009-06-05
EP2094256A4 (en) 2009-11-11
BRPI0710595A2 (pt) 2011-08-16
NZ571467A (en) 2009-03-31

Similar Documents

Publication Publication Date Title
AR068669A1 (es) Metodo para aliviar la queratoconjuntivitis seca
BRPI0820171B8 (pt) compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos
CL2021000907A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020)
AR064077A1 (es) Composiciones bajo forma de unguento sin vaselina que comprende un derivado de vitamina d y eventualmente un anti-inflamatorio esteroide
JP2014527964A5 (es)
UY31272A1 (es) Nuevos derivados de ácido azabifenilaminobenzoico
CR20140544A (es) Compuestos para inhibir la progresión mitotica
CL2007003491A1 (es) Forma cristalina del acido (3s)-3-[n-(n-(2-tercbutilfenil)oxamil)alaninil]amino-5(23,5,6-tetrafluorofenoxi)-4-oxopentanoico; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar la fibrosis hepatica.
CU20100238A7 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
SV2009002903A (es) Compuestos para la inhibicion de enzimas
CO6321221A2 (es) Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
UY31922A (es) Compuestos
CL2004000848A1 (es) Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
CL2017001913A1 (es) Composición tópica curativa
CL2008003576A1 (es) Compuestos derivados de amida del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y usos en el tratamiento de una afeccion inflamatoria.
BR112015023761A2 (pt) moduladores de molécula pequena de pcsk9 e seus métodos e usos
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
EA201071235A1 (ru) Жидкая композиция для деферипрона с приятным вкусом
BRPI1007287B8 (pt) composto de carboxamida, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
CO2018002198A2 (es) Composiciones farmacéuticas que comprenden un compuesto oligomérico para modular la expresión de apolipoproteína (a)
CL2010001566A1 (es) Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune.
CY1115516T1 (el) Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα

Legal Events

Date Code Title Description
FB Suspension of granting procedure